Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05798481 · ClinicalTrials.gov registry record · Early Phase 1

Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.

A Early Phase 1 study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
Early Phase 1
Development phase
14
Enrollment target

NCT05798481 is a Early Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 14 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05798481, a Early Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
Early Phase 1
Development phase
14 participants
Enrollment target

Study Summary

The purpose of the study is to increase the in vivo levels of nitric oxide by generating nitric oxide donor compound S-nitrosoacetylcysteine (SNOAC) using the mixture of sodium nitrite and N-acetylcysteine crystals in the sublingual space. The generated SNOAC rapidly diffuses into blood circulation thereby decrease the systemic blood pressure. This compound can be an alternative to organic nitrate NO donor drugs without developing tolerance in patients.

Interventions

  • DRUG Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2024-03-27
Est. Completion 2025-10-05
Phase Early Phase 1

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT05798481

The ClinicalTrials.gov registry entry for NCT05798481 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals. is the first listed.

NCT05798481 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05798481 about?

NCT05798481 is a clinical study titled "Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.". The purpose of the study is to increase the in vivo levels of nitric oxide by generating nitric oxide donor compound S-nitrosoacetylcysteine (SNOAC) using the mixture of sodium nitrite and N-acetylcysteine crystals in the sublingual space. The generated SNOAC rapidly diffuses into blood circulation ...

What is the current status of trial NCT05798481?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2024-03-27. Estimated completion is 2025-10-05.

What interventions are being tested in trial NCT05798481?

The interventions under investigation include: Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals. (DRUG).

Who is sponsoring clinical trial NCT05798481?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.